Titan Pharmaceuticals, Inc (NASDAQ:TTNP) Pronounces Availability Of PROBUPHINE™

0
1075

Titan Pharmaceuticals, Inc (NASDAQ:TTNP) is a company that focuses in the manufacture of a wide range of pharmaceutical products. Some of its top-notch products have in the past helped treat serious medical disorders. It was today that the business guru revealed that PROBUPHINE™ was available in its stores.

Current state of affairs

The business giant says that the product is quite effective. It calls upon all patients struggling with opioid dependence to try the product. It supports stability and that is the reason it conducts counseling sessions. Asides from that, it also offers psychological support.

Knight says it is the only one bearing the exclusive right to market and distribute the product in Canada. Titan Pharmaceuticals gave it the license and the terms of the agreement are clear for each of the partiers.

The Chief Executive Officer of Knight Jonathan Ross Goodman opined, “Probuphine offers new hope for those struggling with the issues of compliance, burden and stigmatization that often accompanies opioid dependence. This is a devastating public health crisis.”

Goodman says applauds the company’s management for playing a crucial role in helping enhance lives.

A close outlook

Health Canada at the start of this year approved Probuphine and it promises to provide Knight Therapeutics with all the support it requires. It hopes the partnership will see both parties benefit a huge deal in the long run.

Sunil Bhonsle, the President and CEO of Titan has applauded the unveiling of  Probuphine. According to the official, this product is what the Canadian medical community requires. Patients have been looking forward to solutions that are long-term and effective in handling acute medical conditions.

The U.S President Donald Trump advocates for the manufacture of high end products that will help enhance lives. It was sometime back that the leader signed the Opioid bill. A significant number of Americans saw it as a move targeted towards addressing the opioid crisis.

The leader’s decision pulled along with a desirable impact on the performance. Sources indicate that its earnings rose by about 17%.The company promises to do all within its means towards ensuring it faces out opioid addiction.